Synthesis and Biological Evaluation of Novel Dihydro [2,3D] Pyridine Substituted Enaminosulfonamide Compounds as Potent Human Erythrocyte Carbonic Anhydrase II (hCAII)
The half maximal inhibitory concentration (IC50) values of the compounds were determined to be between 27.03 and 104.39 μM for hCA II and 19.85-76.64 μM for Ki.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Dihydro [2,3D] pyridine substituted enaminosulfonamide compounds have been synthesized and their effects on carbonic anhydrase II (hCAII) have been evaluated.
📊
Temel Bulgular & Veri:Pyrido [2,3 d] pyrimidines were synthesized from barbituric acid derivatives, malonanitrile, aldehyde derivatives in basic condition and then hydrolyzed with hydrochloric acid.
💡
Sonuç & Katkı:The half maximal inhibitory concentration (IC50) values of the compounds were determined to be between 27.03 and 104.39 μM for hCA II and 19.85-76.64 μM for Ki.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Barbituric acid · Carbonic anhydrase II · Dihydro 2 3 D pyridine
Abstract
Dihydro [2,3D] pyridine substituted enaminosulfonamide compounds have been synthesized and their effects on carbonic anhydrase II (hCAII) have been evaluated. Pyrido [2,3 d] pyrimidines were synthesized from barbituric acid derivatives, malonanitrile, aldehyde derivatives in basic condition and then hydrolyzed with hydrochloric acid. The targeted compounds were syn-thesized from amino sulfanilamide, dihydro [2,3D] pyridine compounds, and triethylorthoformate. 1H NMR, 13C NMR, FT-IR and elemental analysis were used for the structural analysis of the compounds. The half maximal inhibitory concentration (IC50) values of the compounds were determined to be between 27.03 and 104.39 μM for hCA II and 19.85-76.64 μM for Ki.
DEMİRCİ, T., ÖZDEMİR, O., KAYA, M. O., ARSLAN, M. (2021). Synthesis and Biological Evaluation of Novel Dihydro [2,3D] Pyridine Substituted Enaminosulfonamide Compounds as Potent Human Erythrocyte Carbonic Anhydrase II (hCAII). Sakarya University Journal of Science, Cilt: 25 Sayı: 1, 200–211. https://ajindex.com/articles/941851
M. Conrad and M. Guthzeit, “Ueber Barbitursäurederivate,” Berichte der Dtsch. Chem. Gesellschaft, vol. 15, no. 2, pp. 2844–2850, Jul. 1882
J. T. Mason, J. W. Baker, and F. Pilcher, “Sodium amytal in surgical management,” Am. J. Surg., vol. 9, no. 1, pp. 9–15, Jul. 1930
N. Moussier, L. Bruche, F. Viani, and M. Zanda, “Fluorinated Barbituric Acid Derivatives: Synthesis and Bio-activity,” Curr. Org. Chem., vol. 7, no. 11, pp. 1071–1080, Jul. 2003
A. Barakat et al., “New Diethyl Ammonium Salt of Thiobarbituric Acid Derivative: Synthesis, Molecular Structure Investigations and Docking Studies,” Molecules, vol. 20, no. 11, pp. 20642–20658, Nov. 2015
H. R. Bourne, Y. Weinstein, K. L. Melmon, L. M. Lichtenstein, C. S. Henney, and G. M. Shearer, “Modulation of Inflammation and Immunity by Cyclic AMP,” Science (80-. )., vol. 184, no. 4132, pp. 19–28, Apr. 1974
P. M. Epstein and R. Hachisu, “Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts.,” Adv. Cyclic Nucleotide Protein Phosphorylation Res., vol. 16, pp. 303–24, 1984
M. D. Leibowitz et al., “A Novel Insulin Secretagogue Is a Phosphodiesterase Inhibitor,” Diabetes, vol. 44, pp. 68–74, 1995
E. M. Grivsky, S. Lee, C. W. Sigel, D. S. Duch, and C. A. Nichol, “Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine,” J. Med. Chem., vol. 23, no. 3, pp. 327–329, Mar. 1980
Y. Hamamoto and N. Yamamoto, “Anti-Fas monoclonal antibody is cytocidal to human,” Proc. Nati. Acad. Sci., vol. 87, no. December, pp. 2–6, 1990
L. K. Wathen, “Method Of Preventing Or Treating Atherosclerosis Or Restenosis,” US 2004/0067947 A1, 2004
W. B. Schwartz, “The Effect of Sulfanilamide on Salt and Water Excretion in Congestive Heart Failure,” N. Engl. J. Med., vol. 240, no. 5, pp. 173–177, Feb. 1949
C. C. L. Quianzon and I. E. Cheikh, “History of current non-insulin medications for diabetes mellitus,” J. Community Hosp. Intern. Med. Perspect., vol. 2, no. 3, pp. 19081, Jan. 2012
N. K. Terrett, A. S. Bell, D. Brown, and P. Ellis, “Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction,” Bioorg. Med. Chem. Lett., vol. 6, no. 15, pp. 1819–1824, Aug. 1996
C. R. Fischer, Jnos; Ganellin, Analogue-based Drug Discoveryا. 2006
S. Dadiboyena and A. T. Hamme II, “Synthesis of Celecoxib and Struct